mRNA vaccine in cancer therapy: Current advance and future outlook

  • Li Y
  • Wang M
  • Peng X
  • et al.
N/ACitations
Citations of this article
102Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS‐CoV‐2 mRNA vaccines have contributed tremendously against SARS‐CoV2, which has prompted the arrival of the mRNA vaccine research boom, especially in the research of cancer vaccines. Compared with conventional cancer vaccines, mRNA vaccines have significant advantages, including efficient production of protective immune responses, relatively low side effects and lower cost of acquisition. In this review, we elaborated on the development of cancer vaccines and mRNA cancer vaccines, as well as the potential biological mechanisms of mRNA cancer vaccines and the latest progress in various tumour treatments, and discussed the challenges and future directions for the field.

Cite

CITATION STYLE

APA

Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., … Li, X. (2023). mRNA vaccine in cancer therapy: Current advance and future outlook. Clinical and Translational Medicine, 13(8). https://doi.org/10.1002/ctm2.1384

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free